Medical treatment technology, Diagnostic technology

# Oligomannose-coated Liposomes (OML); Novel Drug Delivery System

## Life Sciences

Keywords: Oligomannose-coated Liposomes, Macrophage Cellular Vehicle, Disease Control by Immunoregulation

Organizations Involved

○ Naoya Kojima, Ph.D. Professor, Dept. Applied Biochemistry, Tokai University

○ Yuichiro Satoh, President, Bio Med Core Co., Ltd. (BMC)

N.Kojima

Y.Satoh

## 【Abstract】

Tokai University (Tokai) exclusively licensed Bio Med Core (BMC) the patent “Liposome with oligosaccharide on surface” with a package of technology for OML, a fruit of Glycoengineering research at Tokai. BMC plans to develop new therapeutics for cancer and Th1 adjuvants (vaccines for cancer and infectious diseases, and anti-allergies). Tokai supports BMC through the long-term collaborative research agreement, by offering the research space and by conducting promotional activities such as joint press conferences and exhibition at the technology transfer events.

## [Summary of the technology transfer]

## Technological Impact

OML bind to mannose receptors on the surface of macrophages or dendritic cells and are incorporated into those cells. They then migrate to and deliver OML to lymphoid tissues. (Macrophage Cellular Vehicle)

A carrier of anti-cancer agents for metastasized cancer at lymphoid tissues OML are incorporated to macrophages and dendritic cells and effectively exhibit the encapsulated antigens to both MHC class I and II. (Disease Control by Immunoregulation)

Vaccines for infectious diseases by introducing Th1 immune response

▶ Anticancer agents by introducing antigen specific CTL

☑ Anti allergy agents by suppressing Th2 immune response

## Market Impact

BMC plans to develop new businesses on Nanotargeting Devices with OML technologies. The products and anticipated market size are;

Anticancer agents encapsulated OML..... ¥18B (US$156M)

Vaccines for infectious diseases and cancer.....¥40B (US$450M)

Anti allergy agents (Influenza).....¥150B (US$1.3B)

BMC opens new world of Glyco Pharmaceuticals with OML technologies.

BMC introduces new concept of preventive medicines as well as therapeutic medicines for recurrent ATL, chronic infectious diseases and cancer.

## Project Background

Satoh, then Assoc. Prof. of Nagoya-Univ, found OML as epoch-making technology and proposed Tokai a joint plans for pharmaceutical business. Kojima loved his plan and decided to join BMC as CTO.

## Funding History

Funds from ;

New Energ. Indus. Tech. Dev.Org.(NEDO)

2005~2007

Min. Eco. Trade and Indus. (METI) 2006

## I ntellectual property protection

"Liposome with oligosaccharide on surface"

Patent # 2828391

“Drug delivery system using immunological system” etc. Patent Application

## Tumor growth at Omentum

Inhibition of metastasized gastric cancer in peritoneal cavity (top) and drug delivery to omentum by OML (bottom)

## Turning point in the Project

OOML is a carrier of pharmaceuticals. It is a key for success for BMC to collaborate with pharmaceutical companies with good candidates.

OA support of the scientific society on the advanced medicine and a close collaboration with hospitals are key for successful clinical development.